EGFR P-loop and αC-helix compressing (PACC) mutations account for approximately 12% of all epidermal growth factor receptor alterations in non–small cell lung cancer, representing a distinct structural subclass that demands specialized diagnostic testing and targeted therapies, according to presentation data shared by Xiuning Le at the 27th Annual International Lung Cancer Congress.
Defining EGFR PACC Mutations and Genomic Incidence
PACC mutations were first classified as a distinct structural subgroup of EGFR alterations in 2021. According to findings reviewed by Le, an associate professor of thoracic/head and neck medical oncology at The University of Texas MD Anderson Cancer Center in Houston, these variants sit proximal to the drug-binding pocket and directly or indirectly compress the P-loop and αC-helix.
Large genomic databases peg the incidence of these variants between 11% and nearly 14%. Foundation Medicine identified PACC mutations in roughly 20,000 EGFR cases at 13.7%, while a Guardant Health dataset of 22,501 EGFR variants reported an 11.6% incidence. Guardant Inform and aggregated multi-database cohorts show similar figures ranging from 11% to 11.7%. These numbers mean PACC mutations run roughly 1.5- to 2-fold more common than exon 20 insertions across identical datasets.
Furthermore, PACC variants appear more frequently as compound mutations than classical alterations do. Phased sequencing data show that compound PACC variants like E709X and G719X essentially always occur on the same allele. Preclinical modeling in EGFR-mutant Ba/F3 cells indicates these compound mutations show reduced sensitivity to first- and third-generation tyrosine kinase inhibitors compared with classical EGFR mutations.
Clinical Data for Silevertinib in Treatment-Naive NSCLC
Silevertinib (BDTX-1535) is a covalent, central nervous system-penetrant fourth-generation EGFR TKI designed for broad mutation coverage. Data from cohort 3 of a phase 2 dose-expansion study evaluated 43 treatment-naive patients with non-classical mutation-positive NSCLC receiving a 200-mg once-daily dose, with CNS MRI surveillance every six weeks, as detailed at the 2026 ASCO Annual Meeting.
Patients on silevertinib achieved a preliminary median progression-free survival of 15.2 months with a 95% confidence interval spanning from 10.8 months to not estimable, according to trial findings. The median duration of response had not been reached with a range of 7.0 months to not estimable, while 23 patients remained on active therapy. Notably, no patients developed de novo brain metastases during the study.
Pro Tip: When evaluating atypical EGFR variants, clinicians should check whether local molecular pathology platforms annotate structural subgroups like PACC, as these distinctions alter predicted drug sensitivities.
Emerging Agents: Firmonertinib, Enozertinib, and Afatinib
Clinical evaluation of firmonertinib in the prospective phase 1b FURTHER study marks the first trial to use PACC as a formal classifier for patient enrollment, according to data presented by Le and co-investigators. Treatment-naive patients with PACC-mutated NSCLC were randomly assigned to daily doses of 160 mg or 240 mg.
Patients receiving the 240-mg dose (n = 22) achieved a confirmed overall response rate of 68.2% and a disease control rate of 100%. By comparison, the 160-mg dose cohort (n = 23) recorded a confirmed overall response rate of 34.8%. Median progression-free survival reached 16.0 months at the higher dose versus 11.1 months at the lower dose, though the difference did not hit statistical significance with a hazard ratio of 0.728 and a $P$ value of .4672.
Meanwhile, enozertinib (ORIC-114) was evaluated in a phase 1/2 study of 22 patients with PACC-mutated NSCLC receiving an 80-mg effective dose. Investigators reported a best overall response rate of 36% and a disease control rate of 91%. Among 13 patients presenting with baseline CNS disease, the best overall response rate was 31%.
For second-generation options, the phase 3 ACHILLES/TORG1834 study compared afatinib with platinum-doublet chemotherapy across 109 patients with uncommon EGFR mutations. Afatinib significantly improved median progression-free survival with a hazard ratio of 0.421 and a $P$ value of .0010, alongside higher overall response rates than chemotherapy. Pooled retrospective data across subtypes like S768I, G719X, and L861Q confirm that second-generation TKIs outperform older or third-generation agents in this space.
Molecular Testing and Pathology Reporting
Diagnostic laboratories are adapting clinical reporting to reflect structural classifications. A side-by-side testing report comparison highlighted by Le demonstrated how tissue-based mutation panels now annotate specific alterations.
For example, an EGFR p.A702T classical-like alteration and an EGFR p.E709A PACC alteration receive distinct structure-function classifications on pathology outputs. These annotations provide treating oncologists with clear predictive guidance regarding differential sensitivities to second- and third-generation TKIs.
Future clinical research priorities outlined by Le include mapping outcomes between single versus compound PACC mutations, evaluating co-mutation landscapes across subgroups, and understanding differences in the tumor microenvironment that influence responses to immunotherapy or antibody-drug conjugates.
Did You Know? PACC mutations are roughly 1.5 to 2 times more common than traditional exon 20 insertions across large genomic databases like Foundation Medicine and Guardant Health.
Frequently Asked Questions
What does PACC stand for in EGFR mutations?
PACC stands for P-loop and αC-helix compressing. These mutations occur close to the drug-binding pocket in non-small cell lung cancer.
How common are EGFR PACC mutations?
According to large genomic databases presented at the International Lung Cancer Congress, PACC mutations account for approximately 11% to 14% of all EGFR alterations in non-small cell lung cancer.
What targeted therapies show activity against PACC mutations?
Clinical trials show promising activity with agents such as silevertinib (BDTX-1535), firmonertinib, enozertinib (ORIC-114), and the second-generation TKI afatinib.
Do first- and third-generation TKIs work well on PACC mutations?
Preclinical data indicate that PACC-mutated tumors generally display reduced sensitivity to standard first- and third-generation tyrosine kinase inhibitors compared with classical EGFR mutations.
Join the Conversation: How is your institution adapting molecular diagnostic panels to capture uncommon EGFR alterations like PACC? Share your thoughts or clinical experiences in the comments below, and subscribe to our oncology newsletter for ongoing updates from major cancer congresses.
Worth a look